WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) is moving toward what could be a defining year, with a late-stage ...
Phase 3 SELVA study evaluating QTORIN rapamycin 3.9% anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in Ma ...
Phase 3 SELVA study evaluating QTORINâ„¢ rapamycin 3.9% anhydrous gel (QTORINâ„¢ rapamycin) for microcystic lymphatic ...
Long COVID affects an estimated 65 million people worldwide and can damage the brain, heart, blood vessels, and immune system ...
Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan ...
Building on their existing collaboration, the companies have signed a new agreement to focus on lead optimization of drug candidates identified by Variational AI’s Enki™ generative AI platform and ...
A new tool provided a validated tumor recurrence and survival risk score for patients with lymph node-negative PanNETs.
Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care LONDON, /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global ...
Scientists have uncovered evidence that two defining features of cancer are driven by the same underlying molecular process. These features include ...
A protein once thought to simply help cancer cells avoid death turns out to do much more. MCL1 actively drives cancer ...
A new study reveals how a single cancer protein may simultaneously drive tumor survival and metabolic control, uncovering a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback